← All trials
NCT06522854
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2025
- Primary completion
- May 31, 2026
- Completion date
- Nov 30, 2026
- First posted
- Jul 26, 2024
- Last posted
- Nov 4, 2024
- Enrollment
- 2000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Alabama, BirminghamLead sponsor
- National Health and Medical Research Council, AustraliaCollaborator
- University of Alabama, BirminghamSponsor investigator
- University of QueenslandCollaborator
- University of LagosCollaborator
- University of Alabama, BirminghamOfficial
- Ladoke Akintola University of Technology Teaching Hospital, OgbomosoCollaborator
- Lagos State UniversityCollaborator
- Mater Medical Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.